Heron Therapeutics (HRTX) Q4 2025: Acute Care Franchise Surges 57% as Commercial Expansion Accelerates
Acute care products delivered a breakout quarter, validating Heron’s targeted commercial investments and reimbursement strategy. Oncology remains a stable base, but management is leaning aggressively into high-opportunity acute care markets for 2026. Guidance signals a deliberate trade-off: near-term EBITDA moderation in exchange for outsized top-line growth and market share capture.
Summary
- Acute Care Inflection: Heron’s focused commercial execution unlocked rapid growth in its acute care franchise.
- Oncology Resilience: The oncology business provides a steady foundation as the company pivots resources to higher-growth assets.
- Strategic Expansion: Management is prioritizing targeted field force expansion to maximize market penetration in 2026.
Performance Analysis
Heron Therapeutics’ Q4 2025 results mark a decisive pivot toward accelerated acute care growth. The company’s acute care franchise, which includes Zinderlef, pain management, and Oponvy, antiemetic for post-operative nausea, posted a 57% year-over-year revenue increase in the quarter, with Zinderlef up 48% and Oponvy nearly doubling. This surge was driven by a combination of improved distributor incentives, workflow simplification, and critical reimbursement wins—most notably, the rollout of a permanent J-code for Zinderlef and inclusion of Oponvy in new clinical guidelines.
Oncology supportive care, anchored by Sinvanti, remained a stable contributor despite a planned wind-down of Sustol, a legacy product. Oncology net sales declined modestly, as expected, but provided over $105 million in annual revenue and continued to underpin the company’s financial stability. Gross margins reached 73% for the year, reflecting disciplined cost management and a favorable product mix shift toward higher-growth assets. Adjusted EBITDA exceeded guidance, and the company’s recent refinancing removed a major capital structure overhang, giving Heron financial flexibility to invest in expansion.
- Commercial Execution Drives Growth: Acute care revenue acceleration was supported by the Crosslink Ignite distributor program and dedicated sales resources for Oponvy.
- Reimbursement and Access: Permanent J-codes and consensus guideline inclusion reduced hospital adoption friction and solidified product positioning.
- Oncology Stability Amid Transition: Sinvanti’s resilience offset the planned decline of Sustol, ensuring a reliable revenue base as acute care ramps.
Heron’s exit rate and momentum into 2026 suggest continued top-line strength, though management cautions that increased commercial investment will dampen EBITDA growth in the near term.
Executive Commentary
"With a solid capital structure now in place, management can concentrate fully on commercial execution, product expansion, and delivering sustained growth."
Craig Collard, Chief Executive Officer
"This marks an important milestone. Heron is demonstrating the ability to grow revenue at a meaningful rate without sacrificing financial discipline."
Dara Duarte, Chief Financial Officer
Strategic Positioning
1. Acute Care Market Penetration
Heron is doubling down on its acute care portfolio, targeting geographies with proven access, reimbursement, and distributor traction. The focus is on scaling commercial teams where foundational success factors already exist, maximizing efficiency and accelerating revenue pull-through.
2. Reimbursement and Guideline Leverage
Permanent J-codes for both Zinderlef and Oponvy, along with Oponvy’s inclusion in the fifth consensus guidelines for post-operative nausea management, are removing barriers to hospital adoption. These wins provide lasting tailwinds by simplifying coding and validating clinical value for hospital committees and payers.
3. Oncology as a Financial Base
The oncology supportive care business, led by Sinvanti, continues to provide stable cash flow even as Sustol is phased out. This segment’s resilience allows management to redeploy resources toward higher-growth acute care opportunities without jeopardizing overall financial health.
4. Product Lifecycle and Pipeline Progress
Heron is preparing for its next acute care innovation with the pre-filled syringe (PFS) presentation for Zinderlef, targeting FDA approval in mid to late 2027. This pipeline investment signals a commitment to sustaining leadership in acute care settings.
5. Commercial Infrastructure Investments
Management is intentionally increasing commercial spend in 2026 to capture outsized growth potential, accepting a temporary slowdown in EBITDA expansion in favor of long-term market share and revenue acceleration.
Key Considerations
This quarter marks a turning point for Heron’s business model, as management reallocates capital from legacy oncology toward scalable acute care growth. The company’s ability to execute on targeted commercial deployment, leverage reimbursement wins, and maintain financial discipline will be critical for sustaining momentum.
Key Considerations:
- Distributor Incentive Alignment: The Crosslink Ignite program improved focus and account coverage, directly supporting acute care growth.
- Hospital Access and Workflow Simplification: The Vial Access Needle (VAN) and permanent J-codes reduced operational friction and streamlined hospital adoption.
- Guideline Inclusion as a Growth Catalyst: Oponvy’s presence in consensus guidelines is expected to drive adoption cycles throughout 2026, with material impact likely in the back half of the year.
- Financial Flexibility: The completed refinancing and EBITDA discipline provide Heron with the runway to invest in commercial expansion without liquidity risk.
Risks
Competitive intensity in both acute care and oncology remains high, with price erosion expected in the CINV (chemotherapy-induced nausea and vomiting) franchise. The pace of hospital adoption for new products depends on formulary cycles and effective awareness-building, which can introduce timing uncertainty. Legal proceedings, such as ongoing patent litigation, could also create operational distractions or financial risk, though management expresses confidence in its legal position.
Forward Outlook
For Q1 2026, Heron expects:
- Continued acute care revenue growth building on Q4’s momentum
- Normal quarter-to-quarter variability, with performance strengthening as the year progresses
For full-year 2026, management guided to:
- Net product sales of $173 to $183 million
- Adjusted EBITDA of $10 to $20 million, reflecting increased commercial investment
Management underscored that targeted field force expansion and reimbursement tailwinds are expected to drive top-line acceleration, even as near-term EBITDA growth moderates. The pipeline’s next major milestone, the Zinderlef pre-filled syringe, is on track for a mid to late 2027 submission.
Takeaways
- Acute Care Growth Trajectory: Heron’s acute care franchise is in a clear acceleration phase, with commercial and reimbursement initiatives translating into rapid adoption and revenue gains.
- Oncology Provides Stability: Despite competitive and pricing pressures, the oncology segment remains a reliable cash generator, supporting Heron’s pivot to higher-growth markets.
- Execution Focus for 2026: Investors should watch for evidence of continued acute care outperformance, successful field force scaling, and the impact of new clinical guidelines on Oponvy’s adoption curve.
Conclusion
Heron Therapeutics exits 2025 with acute care momentum and a clear plan to capitalize on commercial and reimbursement gains in 2026. While EBITDA growth will pause as investments ramp, the long-term setup is for outsized top-line growth and improved enterprise value.
Industry Read-Through
Heron’s results spotlight a broader trend in specialty pharma: targeted commercial deployment and reimbursement optimization can rapidly unlock growth in underpenetrated hospital markets. Permanent J-codes and clinical guideline inclusion are increasingly critical levers for market access, a playbook relevant for peers in pain management, antiemetics, and adjacent acute care categories. The oncology segment’s stability, even amid pricing headwinds and legacy product phase-outs, illustrates the value of a diversified portfolio that funds innovation. Expect continued industry focus on payer education, workflow simplification, and targeted field force expansion as companies seek to maximize near-term growth while laying groundwork for pipeline-driven sustainability.